Clinical trial
In-patient Study in Patients With Type 2 Diabetes Mellitus
NCT00259896 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00259896 |
|---|---|
| Title | In-patient Study in Patients With Type 2 Diabetes Mellitus |
| Official title | A Randomized, Open-label, Placebo-controlled, Repeat-dose Study to Assess the Pharmacokinetics and Pharmacodynamics of 5 Micrograms Exenatide Administered Subcutaneously Twice Daily for 7 Days in Healthy Normal Volunteers and in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | exenatide |
| Enrollment | 30 |
| Start date | Oct 1, 2005 |
| First posted | Dec 1, 2005 |
| Last update posted | Jun 4, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: